Toward a Personalized Treatment of Hodgkin's Disease

Abstract

In this issue of the Journal, Steidl et al.¹ provide a technically sound and important model for using molecular tools to better predict how various cancers will respond to currently effective treatments. One example of such cancers is Hodgkin's disease, which has been curable in its early stages with radiotherapy and in its advanced stages with combination chemotherapy for almost 40 years. However, until recently, Hodgkin's disease has trailed behind other cancers in the application of molecular analysis because of the rarity of the malignant Reed–Sternberg cell in the lesion and the complex composition of the tumor tissue. Despite . . .